AstraZeneca and Daiichi Sankyo’s Enhertu breast cancer drug significantly helped patients with HER2-low metastatic breast cancer in its phase 3 clinical trial, AstraZeneca said Feb. 21.
Read the full post on Becker's Hospital Review - Healthcare News